Each week, Crowell & Moring’s State Attorneys General team highlights significant actions that State AGs have taken. See our State Attorneys General page for more insights. Below are the updates from April 30-May 7, 2026:

Multistate

• A bipartisan coalition of 45 state attorneys general submitted a letter to the U.S. Department of Labor urging the agency to impose new transparency requirements on pharmacy benefit managers (PBMs) — third-party intermediaries that administer prescription drug benefits on behalf of insurers and exercise control over which drugs are covered and how much they cost for nearly all Americans with health insurance. The coalition called on the Labor Department to mandate that PBMs disclose how they generate revenue on a biannual basis and to allow employers that fund health insurance plans to conduct independent audits of PBM operations. The attorneys general also urged the Department to clarify that any new federal transparency rule would not preempt existing state PBM regulations under the Employee Retirement Income Security Act of 1974 (ERISA) — a federal statute that PBMs have previously invoked in efforts to avoid state oversight.

• A bipartisan coalition of 55 state and territory attorneys general announced that a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family, has become legally effective, concluding nearly a decade of multistate investigation and litigation into the company’s role in fueling the opioid crisis through the marketing of opioid products. The settlement delivers funds for addiction treatment, prevention, and recovery to communities across the country over the next 15 years, provides direct relief to individual victims and other claimants in Purdue’s bankruptcy proceedings, and permanently bars the Sacklers from selling opioids in the United States. In addition to the monetary relief, the settlement requires Purdue and the Sacklers to publicly disclose more than 30 million documents related to their opioid business, and transfers Purdue’s manufacturing operations to a newly formed entity — Knoa Pharma LLC — to be overseen by a board with no prior connection to Purdue and subject to an independent monitor.

Colorado

• Attorney General Weiser announced a settlement with Cruise Management, a property management company operating in Denver and Fort Collins, following an investigation finding that the company unlawfully refused to accept housing vouchers, including Section 8, from prospective tenants in violation of the Colorado Anti-Discrimination Act and the Colorado Consumer Protection Act. Under the terms of the settlement, Cruise Management is required to pay $10,000 to the Housing Rights Initiative, a nonprofit that identified the discriminatory conduct and referred it to the attorney general’s office, and must also adopt written fair housing policies, train relevant employees, and submit a compliance report to the attorney general’s office — while being prohibited from misrepresenting its obligations regarding housing vouchers going forward.

District of Columbia

• Attorney General Schwalb filed a lawsuit against Sequoia Row Consulting, LLC, and its owner and CEO Paul Lawrence, alleging that the company fraudulently obtained over $13 million in DC government contracts by exploiting the District’s Certified Business Enterprise (CBE) program — a program designed to reserve contracting opportunities for small, local, and resident-owned businesses. The complaint alleges that Sequoia Row maintained fraudulent CBE certifications for years despite lacking a principal office in the District and despite its owner residing in Georgia, and that the company used those certifications to secure at least 32 government contracts set aside exclusively for certified local businesses. The lawsuit further alleges violations of DC wage and hour laws, claiming that Sequoia Row misclassified dozens of janitorial workers as independent contractors, depriving them of overtime pay, prevailing wages, paid sick leave, and other legally required benefits; the Office of the Attorney General is seeking recovery of funds paid under the fraudulently obtained contracts, treble damages and civil penalties under the District’s False Claims Act, and restitution for the workers who were illegally misclassified.

Illinois

• Attorney General Raoul announced a $75 million settlement and a $50 million settlement with Peoples Gas Light and Coke Company and North Shore Gas Company that will provide $125 million in bill credits to over one million utility customers in northeastern Illinois, as well as an estimated $350 million in long-term savings resulting from the removal of $130 million in capital costs that would otherwise have been passed on to ratepayers over time. The settlements resolve allegations that Peoples Gas imprudently charged customers — through a monthly Qualified Infrastructure Plant surcharge from 2017 through 2023 — for costs associated with its pipeline replacement program that included ineligible capital work, expired permits, and unsubstantiated change orders, and that both Peoples Gas and North Shore failed to keep customer arrearages under their Uncollectible Expense Adjustment riders within manageable levels. In addition to the monetary relief, the settlements require Peoples Gas to implement a series of accountability and transparency measures governing its ongoing pipeline retirement program, including competitive bidding requirements for contracts in excess of $25,000 and documentation requirements for cost changes — with both settlements subject to approval by the Illinois Commerce Commission.

Maryland

• Attorney General Brown announced that his office’s Antitrust Division reached a $4.5 million settlement with Mylan Inc., the manufacturer and seller of the EpiPen, resolving allegations that the company engaged in anticompetitive conduct to maintain its market dominance over the widely used epinephrine auto-injector and suppress the availability of lower-cost generic alternatives. The attorney general’s investigation found that Mylan entered into exclusionary contracts with pharmacy benefit managers that blocked generic competitors from the market, filed patent lawsuits against competitors and then entered into pay-for-delay settlement agreements, and raised unfounded concerns with the U.S. Food and Drug Administration in order to delay regulatory approval of generic versions of the product. In addition to the $4.5 million payment, the settlement requires Mylan to increase the co-pay coupon for its authorized generic EpiPen from $25 to $40 and to take additional steps to expand access to the product for vulnerable Maryland residents.

Massachusetts

• Attorney General Campbell announced a $5 million settlement with Adroit Health Group LLC and its affiliated entities, a Texas-based private health insurance agency that sold plans to thousands of Massachusetts consumers beginning in 2016, resolving allegations that the company engaged in unfair and deceptive business practices in the marketing and administration of supplemental health insurance products and non-insurance health programs that failed to meet applicable state and federal requirements. The attorney general’s office alleged that Adroit misrepresented its products as comprehensive health coverage meeting federal and state standards, misled consumers about costs and benefits, charged consumers without authorization, failed to provide refunds to consumers who sought to cancel, and operated under multiple business names to further obscure its conduct. A significant portion of the $5 million settlement will be distributed as restitution directly to affected Massachusetts consumers, and Adroit is permanently prohibited from selling, offering, or administering any health insurance policy or non-insurance health program to Massachusetts residents.

New Jersey

• Attorney General Davenport and the Division of Consumer Affairs’ Bureau of Securities issued a Cease and Desist Order against online entity Titan Macro Finance, shutting down an investment fraud scheme carried out through Instagram promotions and a WhatsApp chat group in which Titan Macro operatives posed as “trading mentors” and induced investors to open and fund sham investment accounts, in violation of New Jersey’s Uniform Securities Law. The scheme purportedly followed a pattern of initially permitting small withdrawals to establish credibility, displaying fictitious trading profits to encourage additional deposits, and then demanding previously undisclosed tax and management fees before blocking investors’ access to their accounts entirely and cutting off all communication. The action was coordinated with the California Department of Financial Protection and Innovation, which simultaneously ordered Titan Macro to cease fraudulently offering and selling commodities in violation of the California Commodity Code of 1990, following the loss of $20,316 by at least one California investor recruited through a WhatsApp promotion.

New York

• Attorney General James secured a settlement of more than $5 million from cryptocurrency platform Uphold HQ, Inc. for allegedly misleading investors by promoting CredEarn — a cryptocurrency investment product offered by Cred, LLC — as a safe and reliable savings product, when Cred was generating returns through risky micro-loans to borrowers in China with no credit histories, and when no insurance protecting retail investors from investment losses on digital assets existed despite Uphold’s representations to the contrary. The attorney general’s investigation concluded that Uphold was illegally promoting CredEarn without being registered as a broker or commodity broker-dealer, in violation of New York law. Under the terms of the settlement, Uphold will pay $5 million — more than five times the fees it earned from the product — directly to harmed customers, and will also pass through to customers any payments it receives from Cred’s ongoing bankruptcy proceedings; additionally, Uphold is required to register as a broker with the attorney general’s office and to strengthen its due diligence policies before partnering with or recommending any third-party investment product in the future.